These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 314597)

  • 1. Metoclopramide antagonism of 5-hydroxytryptophan-induced "wet-dog" shake behaviour in the rat.
    Fozard JR; Palfreyman MG
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Jun; 307(2):135-42. PubMed ID: 314597
    [No Abstract]   [Full Text] [Related]  

  • 2. Metoclopramide antagonism of 5-hydroxytryptophan-induced 'wet-dog' shake behaviour in the rat [proceedings].
    Fozard JR; Palfreyman MG
    Br J Pharmacol; 1978 Jun; 63(2):387P-388P. PubMed ID: 307422
    [No Abstract]   [Full Text] [Related]  

  • 3. Involvement of 5-HT2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat.
    Yap CY; Taylor DA
    Neuropharmacology; 1983 Jul; 22(7):801-4. PubMed ID: 6604883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The specificity of neuroleptic- and methysergide-induced behavioral hypersensitivity.
    Klawans HL; D'amico DJ; Nausieda PA; Weiner WJ
    Psychopharmacology (Berl); 1977 Nov; 55(1):49-52. PubMed ID: 414261
    [No Abstract]   [Full Text] [Related]  

  • 5. Quipazine exacerbation of a hyperkinetic syndrome: involvement of brain dopamine and serotonin.
    Langlais PJ; Gabay S
    J Neurosci Res; 1977; 3(2):135-41. PubMed ID: 563925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity.
    Bedard P; Pycock CJ
    Neuropharmacology; 1977 Oct; 16(10):663-70. PubMed ID: 304190
    [No Abstract]   [Full Text] [Related]  

  • 7. L-dopa hypotension in dogs: evidence for mediation through 5-HT release.
    Antonaccio MJ; Robson RD
    Arch Int Pharmacodyn Ther; 1974 Nov; 212(1):89-102. PubMed ID: 4281293
    [No Abstract]   [Full Text] [Related]  

  • 8. Antagonism by methysergide of the effects of L-5-hydroxytryptophan and quipazine on schedule-controlled responding.
    Leander JD
    Neuropharmacology; 1981 Dec; 20(12A):1141-3. PubMed ID: 6976522
    [No Abstract]   [Full Text] [Related]  

  • 9. Antagonism by ketanserin of the behavioral effects of quipazine but not l-5-hydroxytryptophan in squirrel monkeys.
    Witkin JM; Brady LS; Barrett JE
    Psychopharmacology (Berl); 1988; 94(3):302-5. PubMed ID: 3128804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of imipramine-induced rat brain beta-adrenoreceptor desensitization by subacute co-administration of trazodone, zimelidine, quipazine or 5-hydroxytryptophan.
    Alhaider AA; Mustafa AA
    Psychopharmacology (Berl); 1991; 103(3):351-6. PubMed ID: 1647538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of serotoninmimetics in the behavioral despair test in rats.
    Górka Z; Wojtasik E; Kwiatek H; Maj J
    Commun Psychopharmacol; 1979; 3(3):133-6. PubMed ID: 315302
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone.
    Green AR; O'Shaughnessy K; Hammond M; Schächter M; Grahame-Smith DG
    Neuropharmacology; 1983 May; 22(5):573-8. PubMed ID: 6603593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quipazine-metoclopramide inhibition of CB-154-induced prolactin suppression in rats: neurotransmitter-metabolite correlations.
    Lipham LB; Porter JK; Norred WP; Booth NH; Robbins JD
    Proc Soc Exp Biol Med; 1987 Mar; 184(3):250-5. PubMed ID: 2881309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quipazine induced wet dog shake behaviour in rats: mechanism of action.
    Hiremagalur ; Keshavan JH; Dandiya PC; Gurbani NK
    Pharmacol Res Commun; 1980 Sep; 12(8):757-68. PubMed ID: 6160597
    [No Abstract]   [Full Text] [Related]  

  • 15. The 'wet dog shake" behaviour in the rat and 5-hydroxytryptamine [proceedings].
    Bedard P; Pycock C
    Br J Pharmacol; 1977 Mar; 59(3):450P-451P. PubMed ID: 300259
    [No Abstract]   [Full Text] [Related]  

  • 16. Behavioral supersensitivity to 5-hydroxytryptophan induced by chronic methysergide pretreatment.
    Klawans HL; D'Amico DJ; Patel BC
    Psychopharmacologia; 1975 Nov; 44(3):297-300. PubMed ID: 1082146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of central serotonin and dopamine in the regulation of carbaryl-induced tremor.
    Ray SK; Poddar MK
    Eur J Pharmacol; 1990 Jun; 181(3):159-66. PubMed ID: 1696544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of tolerance to the wet-dog shake behaviour but not the increase in seizure threshold induced by L-5-hydroxytryptophan during continued treatment in rats.
    Pagliusi SR; Löscher W
    Psychopharmacology (Berl); 1985; 86(1-2):118-24. PubMed ID: 2410943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy.
    Balsara JJ; Jadhav JH; Chandorkar AG
    Psychopharmacology (Berl); 1979 Mar; 62(1):67-9. PubMed ID: 108749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin receptor activation in rats previously deprived of REM sleep.
    Santos R; Carlini EA
    Pharmacol Biochem Behav; 1983 Apr; 18(4):501-7. PubMed ID: 6602989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.